What do the Pathos AI and Tempus AI deals give Bristol Myers Squibb?

Pathos AI provides exclusive access to its discovery platform for neuroscience projects. Tempus AI provides multi-year data licensing that connects real-world patient information with AI tools across Bristol Myers Squibb's pipeline.

How will Bristol Myers Squibb measure whether the AI and trial access push is working?

The clearest proof point is whether the tools show up in trial design and readouts, such as faster enrollment or more targeted neurological and oncology cohorts disclosed in 2027 study updates.

What is the application deadline for the IHI Cancer Collective Action Collaborative?

Sites have until November 30, 2026 to apply, and how many join by then will be a practical test of the trial access effort.

AI in HealthcareTop Companies' AI MovesAI Business & IndustryTop Companies AI6m agoOct 26, 2026, 06:30 JST

Bristol Myers Squibb taps Pathos AI, Tempus AI in multi-year drug discovery deals

Send on LINE

3 Key Points

What happened
Bristol Myers Squibb entered multi-year AI drug development partnerships with Pathos AI and Tempus AI. It gains exclusive access to Pathos AI's discovery platform for neuroscience projects and multi-year data licensing from Tempus AI that connects real-world patient information with AI tools across its pipeline.
Why it matters
The deals plug Bristol Myers Squibb into large, curated neurological and oncology datasets it can query with specialized AI tools. That is designed to sharpen drug target selection, match patients to studies more efficiently and tighten feedback loops between real-world outcomes and lab work.
What to watch
The clearest proof point will be whether faster enrollment or more targeted neurological and oncology cohorts show up in trial design and readouts disclosed in 2027 study updates.

WHO IT HITSThis lands on Bristol Myers Squibb's R&D teams and clinical trial operations, which will need to feed the new datasets and AI tools into target selection and patient matching. It also affects the neuroscience and oncology research groups whose projects will run through the Pathos AI platform.

Not sure about something? Ask the AI

Questions and answers are published on this page.

Summaries like this, every morning.

Get these free every morning

Context & Analysis

The agreements come as Bristol Myers Squibb, a biopharmaceutical group with a market value of about $128.7b, looks to data-driven drug research to support its growth story. Its existing narrative already highlights AI-enabled R&D partnerships and a growing neuroscience and immunology portfolio, and these deals extend AI into neurology while linking it to real-world data.

The company's research push is not limited to AI. It also launched a national collaboration with the Institute for Healthcare Improvement to broaden access to cancer clinical trials, and the IHI Cancer Collective Action Collaborative will track how many sites join by the November 30, 2026 application deadline. Together, the AI partnerships and the trial access effort sit against broader shifts in how Bristol Myers Squibb pursues research.

How much these moves change the outlook may depend on whether the AI tools and wider trial access translate into tangible study results. The company's fair value is put at $66.71, and investors will be watching for faster enrollment or more targeted cohorts in 2027 study updates as early signals.

FAQ

What do the Pathos AI and Tempus AI deals give Bristol Myers Squibb?: Pathos AI provides exclusive access to its discovery platform for neuroscience projects. Tempus AI provides multi-year data licensing that connects real-world patient information with AI tools across Bristol Myers Squibb's pipeline.
How will Bristol Myers Squibb measure whether the AI and trial access push is working?: The clearest proof point is whether the tools show up in trial design and readouts, such as faster enrollment or more targeted neurological and oncology cohorts disclosed in 2027 study updates.
What is the application deadline for the IHI Cancer Collective Action Collaborative?: Sites have until November 30, 2026 to apply, and how many join by then will be a practical test of the trial access effort.

AI news that matters for your work, delivered every morning.

Pick your industry and the AI tools you use, and get news related to your work every day.

Get it free

Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →

Ask AI

Ask AI anything about this article. The AI reads this article, earlier AIToday articles, and Wikipedia, and cites its sources. Q&As are published on this page for other readers too.